The global Recombinant Plasma Protein Therapeutics Market size is estimated to grow at CAGR above 8.3 % over the forecast time frame 2019-2026 and reach the market value around USD 17.1 billion by 2026. It is expected that plasma derived protein will be replaced by recombinant plasma products, the number of products being launched will be increased, and demand for new therapies for hemophilia therapy will increase. Segment Insights Based on drug class, cell line and indications, the worldwide recombinant plasma protein treatment market has been broken down. Based on the class of the Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
medicines, recombinant clotting and human esterase inhibitors have been classified in the market. A further subsegment of recombinant coagulation factor VIII, recombinant factor IX, recombinant factor VIIa and others was found in the segment of re-combinant coagulatory factors. Recombinant coagulation factor VIII is projected by 2027, due to an increase in homophile A cases worldwide, new product launches and the utilization of recombinant plasma protein therapy for treating Hemophilia A, to make a major portion of the recombinant coagulation factor segment in the market by 2026. The VIIa sub-segment of the recombinant coagulation factor is expected to expand steadily over the forecast period. The Chinese hamster ovary cells (CHO), the baby kidney (BHK), the human embryonic kidney (HEK) cells, and more were categorized as a cell line in the market. Increased utilization of CHO cell lines for the production of therapeutic products is expected to expand to a prominent CAGR in the Chinese cell line (CHO). Based on indication, hemophilia B, hemophilia A, von Willebrand and others were separated from the market. Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/reques t-sample/1308 Regional Outlook The market will be driven by the rise in the numbers of rare hematology diseases in Asia-Pacific, by the increase in recombinant DNA technology for therapeutic use and by increased R&D spending by companies in pharmaceuticals and biotechnology. In addition, in Japan and China, a growth opportunity is created in the market for recombinant coagulation factors of the third generation. Government and NGOs are currently trying to raise awareness of hemophilia A and B and help the general population understand the cases, diagnoses, and methods of treatment for rare diseases. Currently, with regulatory authorities, countries like China, Japan, Australia and New Zealand have been converted to hemophilia A standard recombinant plasma therapy. 80 percent of patients with bleeding chaos are treated with recombinant coagulation factors according to the Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
Hemophilia Foundation Australia (HFA). Therefore, an increase in recombinant therapies is projected to drive the market during the predicted period for hemophilia treatment. Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs Key Players and Strategies The Recombinant Plasma Protein Therapeutics market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Bayer AG, Novo Nordisk A / S, Aptevo Therapeutics, Octapharma, Pharma Group NV, Bioverativ Therapeutics, Inc. (Sanofi),Pfizer Inc., and CSL Limited, Shire (Takeda Pharmaceutical Company Limited) among others. These companies are able to expand their global market presence through new product launch, purchasing, geographical expansion, collaborations and distribution agreements. Takeda Pharmaceutical Company Limited, a pharmaceutical company based in Japan, was acquired by Shire in January 2019. This acquisition aims to strengthen the geographic presence of Takeda Pharmaceutical Company Limited. Bioverativ Therapeutics Inc., which operates as part of Sanofi Genzyme, has been acquired by Sanofi, the leading pharmaceutical company, in January 2018. Many other players on the market have also taken steps to expand their business in emerging markets. Leading players in the Asia Pacific, such as China, Japan and Australia, also concentrate on increasing their customer base. Market participants are also supporting several campaigns to increase awareness about hematological disorder and the availability and advantages offered by such products of treatments, such as recombinant plasma proteins.
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/pressreleases TABLE OF CONTENT CHAPTER 1. INDUSTRY OVERVIEW 1.1. Definition and Scope 1.1.1. Definition of Recombinant Plasma Protein Therapeutics 1.1.2. Market Segmentation 1.1.3. List of Abbreviations 1.2. Summary 1.2.1. Market Snapshot 1.2.2. Recombinant Plasma Protein Therapeutics Market By Drug Class 1.2.2.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Drug Class (2015-2026) 1.2.2.2. Global Recombinant Plasma Protein Therapeutics Market Revenue Share By Drug Class in 2017 1.2.2.3. Human C1 Esterase Inhibitor 1.2.2.4. Recombinant Coagulation Factors 1.2.2.5. Others 1.2.3. Recombinant Plasma Protein Therapeutics Market By Cell Line 1.2.3.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Cell Line (2015-2026) 1.2.3.2. Chinese Hamster Ovary (CHO) Cell Line 1.2.3.3. Human Embryonic Kidney (HEK) Cell Line 1.2.3.4. Baby Hamster Kidney (BHK) Cell Line 1.2.3.5. Others 1.2.4. Recombinant Plasma Protein Therapeutics Market By Indication 1.2.4.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Indication (2015-2026) 1.2.4.2. Hemophilia B Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
1.2.4.3. Hemophilia A 1.2.4.4. Von Willebrand Disease 1.2.4.5. Others 1.2.5. Recombinant Plasma Protein Therapeutics Market by Geography 1.2.5.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026) 1.2.5.2. North America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026) 1.2.5.3. Europe Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026) 1.2.5.4. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026) 1.2.5.5. Latin America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026) 1.2.5.6. Middle East and Africa (MEA) Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026) CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS 2.1. Market Drivers 2.2. Restraints and Challenges 2.3. Growth Opportunities 2.4. Porter’s Five Forces Analysis 2.4.1. Bargaining Power of Suppliers 2.4.2. Bargaining Power of Buyers 2.4.3. Threat of Substitute 2.4.4. Threat of New Entrants 2.4.5. Degree of Competition 2.5. Value Chain Analysis 2.6. Cost Structure Analysis 2.6.1. Raw Material and Suppliers 2.6.2. Manufacturing Process Analysis 2.7. Regulatory Compliance Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
2.8. Competitive Landscape, 2017 2.8.1. Player Positioning Analysis 2.8.2. Key Strategies Adopted By Leading Players CHAPTER 3. MANUFACTURING PLANTS ANALYSIS 3.1. Capacity and Commercial Production Date of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 3.2. Manufacturing Plants Distribution of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 3.3. R&D Status and Technology Source of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 3.4. Raw Materials Sources Analysis of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 CHAPTER 4. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY DRUG CLASS 4.1. Global Recombinant Plasma Protein Therapeutics Revenue By Drug Class 4.2. Human C1 Esterase Inhibitor 4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.3. Recombinant Coagulation Factors 4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.4. Other 4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) CHAPTER 5. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY CELL LINE 5.1. Global Recombinant Plasma Protein Therapeutics Revenue By Cell Line 5.2. Chinese Hamster Ovary (CHO) Cell Line Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 5.3. Human Embryonic Kidney (HEK) Cell Line 5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 5.4. Baby Hamster Kidney (BHK) Cell Line 5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 5.5. Others 5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) CHAPTER 6. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY INDICATION 6.1. Global Recombinant Plasma Protein Therapeutics Revenue By Indication 6.2. Hemophilia B 6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 6.3. Hemophilia A 6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 6.4. Von Willebrand Disease 6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 6.5. Others 6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
CHAPTER 7. NORTH AMERICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 7.1. North America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million) 7.2. North America Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%) 7.3. U.S. 7.3.1. U.S. Recombinant Plasma Protein Therapeutics Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 7.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 7.4. Canada 7.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 7.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 7.5. Mexico 7.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 7.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) CHAPTER 8. EUROPE RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 8.1. Europe Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million) 8.2. Europe Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%) 8.3. UK 8.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 8.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 8.4. Germany Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
8.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 8.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 8.5. France 8.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 8.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 8.6. Spain 8.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.6.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 8.6.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 8.7. Rest of Europe 8.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.7.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 8.7.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) CHAPTER 9. ASIA-PACIFIC RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 9.1. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million) 9.2. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%) 9.3. China 9.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 9.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 9.4. Japan 9.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 9.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 9.5. India 9.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
9.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 9.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 9.6. Australia 9.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.6.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 9.6.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 9.7. South Korea 9.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.7.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 9.7.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 9.8. Rest of Asia-Pacific 9.8.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.8.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 9.8.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) CHAPTER 10. LATIN AMERICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 10.1. Latin America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million) 10.2. Latin America Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%) 10.3. Brazil 10.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 10.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 10.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 10.4. Argentina 10.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 10.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 10.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 10.5. Rest of Latin America 10.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
10.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 10.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) CHAPTER 11. MIDDLE EAST RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 11.1. Middle East Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million) 11.2. Middle East Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%) 11.3. Saudi Arabia 11.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 11.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 11.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 11.4. UAE 11.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 11.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 11.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 11.5. Rest of Middle East 11.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 11.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 11.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) CHAPTER 12. AFRICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 12.1. Africa Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million) 12.2. Africa Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%) 12.3. South Africa 12.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 12.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
12.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 12.4. Egypt 12.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 12.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 12.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 12.5. Rest of Africa 12.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 12.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 12.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) CHAPTER 13. COMPANY PROFILE 13.1. Octapharma 13.1.1. Company Snapshot 13.1.2. Overview 13.1.3. Financial Overview 13.1.4. Type Portfolio 13.1.5. Key Developments 13.1.6. Strategies 13.2. Novo Nordisk A / S 13.2.1. Company Snapshot 13.2.2. Overview 13.2.3. Financial Overview 13.2.4. Type Portfolio 13.2.5. Key Developments 13.2.6. Strategies 13.3. Bayer AG 13.3.1. Company Snapshot 13.3.2. Overview 13.3.3. Financial Overview 13.3.4. Type Portfolio 13.3.5. Key Developments 13.3.6. Strategies Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
13.4. Bioverativ Therapeutics, Inc. (Sanofi) 13.4.1. Company Snapshot 13.4.2. Overview 13.4.3. Financial Overview 13.4.4. Type Portfolio 13.4.5. Key Developments 13.4.6. Strategies 13.5. Aptevo Therapeutics 13.5.1. Company Snapshot 13.5.2. Overview 13.5.3. Financial Overview 13.5.4. Type Portfolio 13.5.5. Key Developments 13.5.6. Strategies 13.6. Pharma Group NV 13.6.1. Company Snapshot 13.6.2. Overview 13.6.3. Financial Overview 13.6.4. Type Portfolio 13.6.5. Key Developments 13.6.6. Strategies 13.7. Pfizer Inc. 13.7.1. Company Snapshot 13.7.2. Overview 13.7.3. Financial Overview 13.7.4. Type Portfolio 13.7.5. Key Developments 13.7.6. Strategies 13.8. CSL Limited 13.8.1. Company Snapshot 13.8.2. Overview 13.8.3. Financial Overview Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
13.8.4. Type Portfolio 13.8.5. Key Developments 13.8.6. Strategies 13.9. Shire (Takeda Pharmaceutical Company Limited) 13.9.1. Company Snapshot 13.9.2. Overview 13.9.3. Financial Overview 13.9.4. Type Portfolio 13.9.5. Key Developments 13.9.6. Strategies 13.10. Others 13.10.1. Company Snapshot 13.10.2. Overview 13.10.3. Financial Overview 13.10.4. Type Portfolio 13.10.5. Key Developments 13.10.6. Strategies CHAPTER 14. RESEARCH APPROACH 14.1. Research Methodology 14.1.1. Initial Data Search 14.1.2. Secondary Research 14.1.3. Primary Research 14.2. Assumptions and Scope The report is readily available and can be dispatched immediately after payment confirmation. Buy this premium research Report@ https://www.acumenresearchandconsulting.com/buynow/0/1308
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157